ORIGINAL
Cribado del cáncer de próstata mediante antígeno prostático específico: perspectiva del médico en atención primaria y en el laboratorio clínico
Prostate cancer screening using prostate-specific antigen: The views of general and laboratory physicians
N. Giméneza,b,c,d,
, X. Filellab,e, M. Gavagnachf, J.A. Alluéb, D. Pedrazasa,g, F. Ferrerh,i, Grupo de Estudio sobre Cribado en Cáncer de Próstata ◊
Autor para correspondencia
a Unidad de Investigación, Fundación para la Investigación Mútua Terrassa, Universitat de Barcelona, Barcelona, España
b Comisión del Laboratorio Basado en la Evidencia, Sociedad Española del Laboratorio Médico (SEQC-ML), Barcelona, España
c Committee of Evidence-Based Laboratory Medicine (C-EBLM), International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), Milán, Italia
d Laboratorio de Toxicología, Universitat Autònoma de Barcelona, Barcelona, España
e Servicio de Bioquímica y Genética Molecular (CDB), Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, España
f CAP Valldoreix, Fundación para la Investigación Mútua Terrassa, Universitat de Barcelona, Barcelona, España
g ABS Abrera, Direcció d’Atenció Primària Costa de Ponent, Institut Català de la Salut, Barcelona, España
h Servicio de Oncologia Radioterápica. Institut Catalá d’Oncologia (ICO), Institut d’Investigació Biomèdica de Bellvitge (IDIBELL) (Radiobiology and Cancer), L’Hospitalet de Llobregat, Barcelona, España
i Departamento de Ciencias Clínicas-Bellvitge, Universitat de Barcelona, L’Hospitalet de Llobregat, Barcelona, España
Ver másLeído
8503
Vecesse ha leído el artículo
1490
Total PDF
7013
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 26 | 5 | 31 |
| 2025 11 | 125 | 51 | 176 |
| 2025 10 | 147 | 33 | 180 |
| 2025 9 | 108 | 25 | 133 |
| 2025 8 | 117 | 14 | 131 |
| 2025 7 | 95 | 9 | 104 |
| 2025 6 | 93 | 8 | 101 |
| 2025 5 | 109 | 15 | 124 |
| 2025 4 | 129 | 32 | 161 |
| 2025 3 | 105 | 12 | 117 |
| 2025 2 | 101 | 9 | 110 |
| 2025 1 | 84 | 10 | 94 |
| 2024 12 | 98 | 20 | 118 |
| 2024 11 | 119 | 7 | 126 |
| 2024 10 | 94 | 14 | 108 |
| 2024 9 | 59 | 14 | 73 |
| 2024 8 | 58 | 10 | 68 |
| 2024 7 | 54 | 10 | 64 |
| 2024 6 | 83 | 13 | 96 |
| 2024 5 | 54 | 7 | 61 |
| 2024 4 | 82 | 14 | 96 |
| 2024 3 | 90 | 7 | 97 |
| 2024 2 | 110 | 3 | 113 |
| 2024 1 | 111 | 5 | 116 |
| 2023 12 | 85 | 7 | 92 |
| 2023 11 | 91 | 23 | 114 |
| 2023 10 | 92 | 14 | 106 |
| 2023 9 | 94 | 5 | 99 |
| 2023 8 | 84 | 5 | 89 |
| 2023 7 | 148 | 9 | 157 |
| 2023 6 | 115 | 17 | 132 |
| 2023 5 | 147 | 8 | 155 |
| 2023 4 | 129 | 4 | 133 |
| 2023 3 | 135 | 11 | 146 |
| 2023 2 | 86 | 6 | 92 |
| 2022 1 | 106 | 17 | 123 |
| 2022 12 | 70 | 7 | 77 |
| 2022 11 | 91 | 17 | 108 |
| 2022 10 | 74 | 14 | 88 |
| 2022 9 | 114 | 27 | 141 |
| 2022 8 | 78 | 18 | 96 |
| 2022 7 | 57 | 68 | 125 |
| 2022 6 | 55 | 21 | 76 |
| 2022 5 | 69 | 14 | 83 |
| 2022 4 | 55 | 24 | 79 |
| 2022 3 | 69 | 20 | 89 |
| 2022 2 | 89 | 25 | 114 |
| 2021 1 | 122 | 44 | 166 |
| 2021 12 | 86 | 31 | 117 |
| 2021 11 | 105 | 30 | 135 |
| 2021 10 | 56 | 25 | 81 |
| 2021 9 | 85 | 19 | 104 |
| 2021 8 | 68 | 7 | 75 |
| 2021 7 | 64 | 18 | 82 |
| 2021 6 | 60 | 7 | 67 |
| 2021 5 | 64 | 13 | 77 |
| 2021 4 | 125 | 30 | 155 |
| 2021 3 | 79 | 37 | 116 |
| 2021 2 | 53 | 13 | 66 |
| 2020 1 | 72 | 19 | 91 |
| 2020 12 | 53 | 20 | 73 |
| 2020 11 | 57 | 16 | 73 |
| 2020 10 | 44 | 12 | 56 |
| 2020 9 | 44 | 16 | 60 |
| 2020 8 | 59 | 14 | 73 |
| 2020 7 | 56 | 11 | 67 |
| 2020 6 | 63 | 27 | 90 |
| 2020 5 | 76 | 17 | 93 |
| 2020 4 | 48 | 11 | 59 |
| 2020 3 | 190 | 43 | 233 |
| 2020 2 | 105 | 11 | 116 |
| 2020 1 | 80 | 7 | 87 |
| 2019 12 | 76 | 16 | 92 |
| 2019 11 | 75 | 14 | 89 |
| 2019 10 | 76 | 7 | 83 |
| 2019 9 | 75 | 12 | 87 |
| 2019 8 | 48 | 5 | 53 |
| 2019 7 | 69 | 10 | 79 |
| 2019 6 | 61 | 19 | 80 |
| 2019 5 | 91 | 69 | 160 |
| 2019 4 | 49 | 36 | 85 |
| 2019 3 | 13 | 7 | 20 |
| 2019 1 | 1 | 0 | 1 |
| 2018 12 | 4 | 2 | 6 |
| 2018 11 | 3 | 6 | 9 |
| 2018 10 | 5 | 0 | 5 |
| 2018 9 | 68 | 31 | 99 |
| 2018 7 | 1 | 0 | 1 |
| 2018 5 | 0 | 14 | 14 |
| 2018 4 | 0 | 14 | 14 |
| 2018 3 | 0 | 2 | 2 |
Mostrar todo
